RODRIGUEZ OQUENDO ANNABELLE has a total of 13 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2012. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are CURIDIUM LTD, CYTOTECH LABS LLC and FEMALON S P R L.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 5 | |
#2 | WIPO (World Intellectual Property Organization) | 2 | |
#3 | Australia | 1 | |
#4 | Canada | 1 | |
#5 | China | 1 | |
#6 | EPO (European Patent Office) | 1 | |
#7 | Republic of Korea | 1 | |
#8 | Singapore | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Measuring microorganism processes | |
#2 | Medical preparations | |
#3 | Analysing materials | |
#4 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Rodriguez Oquendo Annabelle | 13 |
Publication | Filing date | Title |
---|---|---|
US2017312338A1 | Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases | |
US2015355203A1 | Use of lymphocyte activation gene 3 (LAG-3) expression profiling as a biomarker for assessing inflammasomes, chronic inflammatory diseases and dysfunctional HDL | |
US2013345187A1 | Method for pre-screening and correlation of underlying SCARB1 gene variation to infertility in women and therapeutic use of progestational and other medications in treatment |